Pharmaceutical

Strong Wegovy revenue growth for Novo Nordisk but shares dip

Sales of the GLP-1RA hit $2.5bn in Q3, a 79% increase over the same period last year.

Nov 7, 2024 - 06:00
Strong Wegovy revenue growth for Novo Nordisk but shares dip
Sales of the GLP-1RA hit $2.5bn in Q3, a 79% increase over the same period last year.
Read the original article

Tags:

Previous Article

Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals

Next Article

GSK CEO addresses declining trust in vaccines following Trump re-election

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FTC sues private equity firm Welsh Carson, U.S. Anesthesia Partners for allegedly creating a monopoly

FTC sues private equity firm Welsh Carson, U.S. Anesthe...

Sep 22, 2023

FDA advisory panel recommends a streamlined flu vaccine for next fall

FDA advisory panel recommends a streamlined flu vaccine...

Mar 6, 2024

SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

SGNB-7H4V by Pfizer for Human Epidermal Growth Factor R...

Jun 20, 2024